SCHEMBL3674777

SCHEMBL3674777

O=C(O)c1ccc(N[C@H]2CCc3cc4nc(CO)[nH]c(=O)c4cc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
RECQL P46063 1/20 0.43
PARP1 P09874 4/20 0.42
NPSR1 Q6W5P4 1/20 0.40
PARP14 Q460N5 5/20 0.37
PDE5A O76074 1/20 0.37
BRD4 O60885 1/20 0.36
CYP1A2 P05177 1/20 0.35
TSHR P16473 1/20 0.35
POLB P06746 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
TNKS O95271 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3674775 1.00 KDM4E (0.43) KDM4ERECQLPARP1NPSR1PARP14
SCHEMBL1343569 0.89 PARP1 (0.40) KDM4ERECQLPARP1PARP14PDE5A
SCHEMBL1544255 0.89 PARP1 (0.40) KDM4ERECQLPARP1PARP14PDE5A
SCHEMBL1038155 0.89 PARP1 (0.40) KDM4ERECQLPARP1PARP14PDE5A
SCHEMBL15180107 0.88 PARP1 (0.39) KDM4EPARP1PARP14CYP1A2MEN1
SCHEMBL2318167 0.87 MAPT (0.37) KDM4EPARP1PARP14TNKSTNKS2
SCHEMBL2318171 0.87 MAPT (0.37) KDM4EPARP1PARP14TNKSTNKS2
SCHEMBL2323867 0.86 BRD4 (0.41) KDM4ENPSR1BRD4POLBTDP1
SCHEMBL2323871 0.86 BRD4 (0.41) KDM4ENPSR1BRD4POLBTDP1
SCHEMBL2320352 0.86 PARP1 (0.42) KDM4ERECQLPARP1PARP14PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2213664-B1 PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES BTG INT LTD (GB) 2014-04-30 EP disclosed
EP-2213664-A1 PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES BTG International Limited (GB) 2010-08-04 EP disclosed
US-7250511-B2 Process for the preparation of cyclopenta[g]quinazoline derivatives BTG INTERNATIONAL LIMITED (GB) 2007-07-31 US disclosed
US-20040266798-A1 Process for the preparation of cyclopenta[g]quinazoline derivatives BTG INTERNATIONAL LIMITED (GB) 2004-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266798-A1 Process for the preparation of cyclopenta[g]quinazoline derivatives COX6A1, MT-ND6, CYP2D6 KDM4E 2594/4885RECQL 253/4885PARP1 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.